Please login to the form below
etesevimab
This page shows the latest etesevimab news and features for those working in and with pharma, biotech and healthcare.
Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
Following this, Lilly advanced the further development of bamlanivimab plus another of its neutralising mAbs – etesevimab – to be administered together. ... This represented a 70% risk reduction, with no deaths occurring in the bamlanivimab and
Latest news
-
Pfizer launches early study of COVID-19 antiviral therapeutic
A combination of bamlanivimab and another mAb, etesevimab, has also been approved for emergency use in the US.
-
EMA starts rolling review of Lilly’s COVID-19 antibodies
This represented a 70% risk reduction, with no deaths occurring in the bamlanivimab and etesevimab-treated group. ... After completing its review of the monoclonal antibodies, the CHMP has advised that bamlanivimab and etesevimab can be used together to
-
EMA recommends use of Lilly’s COVID-19 antibody cocktail
Agency concludes bamlanivimab and etesevimab can be used to treat certain COVID-19 patients. ... This represented a 70% risk reduction, with no deaths occurring in the bamlanivimab and etesevimab-treated group.
-
FDA grants emergency use for Lilly’s COVID-19 antibody drug combination
Bamlanivimab plus etesevimab shown to reduce risk of death in high-risk COVID-19 patients. ... This represented a 70% risk reduction, with no deaths occurring in the bamlanivimab and etesevimab-treated group.
-
EMA launches rolling review of Regeneron’s COVID-19 antibody cocktail
This represented a 70% risk reduction, with no deaths occurring in the bamlanivimab and etesevimab-treated group.
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
